Why Novartis ?
About Novartis
Novartis is a global healthcare company, headquartered in Switzerland, created in 1996 through a merge of Ciba-Geigy and Sandoz with a rich history of developing innovative products since the 18th century. As a leading global medicines company, Novartis uses innovative science and digital technologies to create transformative treatments in areas of great medical need.
In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development, with an annual investment of 9-10 billion USD. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Our purpose is to reimagine medicine to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine. Our strategy is to focus on Novartis as a leading medicines company powered by advanced therapy platforms and data science. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at novartis.com
Novartis Mission
Novartis in Vietnam
Novartis has been in Vietnam since the 1950s through its predecessor companies (Sandoz and Ciba-Geigy). In 2008, the Representative Office of Novartis Pharma Services AG was established. In early 2020, Novartis Vietnam Ltd. became the first multinational pharmaceutical company to successfully transform into a foreign-invested enterprise and fully operationalize its import activities. Through long-term commitments, Novartis is supporting the domestic healthcare system and contributing to the socio-economic development of the country.
Today, Novartis is a leader in innovative medicines across many therapeutic areas including Oncology, Immunology & Dermatology, Cardiovascular (hypertension, heart failure, diabetes), Respiratory (Asthma, COPD), Pain relief & Neuroscience, Ophthalmology, Cell & Gene therapy. We are also a leader in high quality generics and biosimilars through our Sandoz unit and one of the largest investors in clinical trials in Vietnam.